AbbVie is trading at a forward price-to-earnings multiple just below 16, significantly below the S&P 500 average of 22 and paired with a five-year PEG ratio around 0.40. This combination suggests the shares are undervalued relative to expected earnings growth. The company’s research and development engine supports this outlook: of approximately 90 distinct compounds, devices or indications in its pipeline, roughly 60 are in mid- to late-stage development. Years of elevated R&D investment have positioned AbbVie to replace revenues lost to patent expirations and to sustain high growth beyond 2030.

In the first nine months of the year, AbbVie generated revenue of $44.5 billion, an 8% increase over the prior year period, while reporting operating earnings of $10.5 billion. The business has navigated the loss of exclusivity on its largest product with limited disruption, and management maintains guidance for high single-digit annual growth out to the end of the decade. Strong margins—driven by a mix of high-value biologics and specialty pharmaceuticals—underpin consistent free cash flow generation, allowing the company to fund R&D and return capital to shareholders.

Looking to 2026, AbbVie’s leadership has outlined two priorities: operational excellence to drive near-term financial performance, and accelerated advancement of late-stage pipeline assets. The company has also signaled plans to expand in the obesity treatment market by leveraging a weight-loss compound licensed last year from Danish biotech Gubra. This move diversifies AbbVie’s growth drivers beyond immunology and oncology, targeting a fast-growing global segment projected to exceed $30 billion by 2030.